ArticleJournal of Cancer2020

Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer.

Fan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.